Canakinumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL-1β |
| Clinical data | |
| Trade names | Ilaris |
| AHFS/Drugs.com | Consumer Drug Information |
| Licence data | EMA:Link, US FDA:link |
| Pregnancy cat. | ? |
| Legal status | ℞-only (US) |
| Routes | intravenous, subcutaneous |
| Identifiers | |
| CAS number | 914613-48-2  |
| ATC code | L04AC08 |
| DrugBank | DB06168 |
| UNII | 37CQ2C7X93  |
| ChEMBL | CHEMBL1201834 |
| Chemical data | |
| Formula | C6452H9958N1722O2010S42 |
| Mol. mass | 145.2 kDa |
 (what is this?) (verify) |
|
Canakinumab (INN, trade name Ilaris, previously ACZ885)[1] is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.[2]
Canakinumab was approved for the treatment of cryopyrin-associated periodic syndromes (CAPS) by the US FDA on June 2009[3] and by the European Medicines Agency in October 2009.[4] CAPS is a spectrum of autoinflammatory syndromes including familial cold autoinflammatory syndrome, Muckle–Wells syndrome, and neonatal-onset multisystem inflammatory disease.
Canakinumab was being developed by Novartis for the treatment of rheumatoid arthritis but this trial has been discontinued.[5] Canakinumab is also in phase I clinical trials as a possible treatment for chronic obstructive pulmonary disease.[6]
[edit] References
- ^ Dhimolea, Eugen (2010). "Canakinumab". MAbs 2 (1): 3–13. doi:10.4161/mabs.2.1.10328. PMC 2828573. PMID 20065636. http://www.landesbioscience.com/journals/mabs/article/10328/.
- ^ Lachmann, HJ; Kone-Paut I, Kuemmerle-Deschner JB et al. (4 June 2009). "Use of canakinumab in the cryopyrin-associated periodic syndrome". New Engl J Med 360 (23): 2416–25. doi:10.1056/NEJMoa0810787. PMID 19494217.
- ^ "New biological therapy Ilaris approved in US to treat children and adults with CAPS, a serious life-long auto-inflammatory disease" (Press release). Novartis. 2009-06-18. http://www.novartis.com/newsroom/media-releases/en/2009/1323528.shtml. Retrieved July 28, 2009.
- ^ Wan, Yuet (29 October 2009). "Canakinumab (Ilaris) and rilonacept (Arcalyst) approved in EU for treatment of cryopyrin-associated periodic syndrome". National electronic Library for Medicines. http://www.nelm.nhs.uk/en/NeLM-Area/News/2009---October/29/Canakinumab-Ilaris-and-rilonacept-Arcalyst-approved-in-EU-for-treatment-of-cryopyrin-associated-periodic-syndrome/. Retrieved 14 April 2010.
- ^ "clinicaltrials.gov, Identifier NCT00784628: Safety, Tolerability and Efficacy of ACZ885 (Canakinumab) in Patients With Active Rheumatoid Arthritis". http://www.clinicaltrials.gov/ct2/show/NCT00784628. Retrieved 2010-08-21.
- ^ Yasothan U, Kar S (2008). "Therapies for COPD". Nat Rev Drug Discov 7 (4): 285. doi:10.1038/nrd2533.
|
|||||||||||||||||||||||||||||||||||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
